SARS-CoV-2 - Remdesivir - Therapeutic Candidates

SARS-CoV-2 - Remdesivir - Therapeutic Candidates


Remdesivir or GS-5734 is an antiviral developed by the American laboratory Gilead Sciences. It is an adenosine-like nucleoside analogue. Remdesivir is what is called a prodrug, meaning that it must be metabolized to obtain an active form. The active form of remdesivir is GS-441524. The mode of action of remdesivir is to disrupt viral RNA polymerase and escape exoribonuclease, which slows down the production of viral RNA. Remdesivir was first used to treat Ebola and Marburg virus infections. It then showed antiviral activity against other RNA viruses such as MERS-CoV and SARS-CoV coronaviruses.
Recently the USA and Japan approved remdesivir for the treatment of SARS-CoV-2. This decision follows a study of more than a thousand Covid-19 patients. However, this study only showed a four-day shortened recovery time from 15 to 11 days in Covid-19 patients.

Search result : 131 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 28
  • Biochemicals 105
  • Inhibitor/Antagonist/Agonist 26
  • Assay 3
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
HY-104077-1mg
 1mg 
HY-104077-5mg
 5mg 
AOB31876-50
 50mg 
AOB31876-5
 5mg 
AOB31876-10
 10mg 
orb1890181-2mg
 2mg 
orb1299527-10mg
 10mg 
orb1299527-25mg
 25mg 
orb746819-5mg
 5mg 
orb1299527-100mg
 100mg 
orb746819-25mg
 25mg 
orb1299527-1mg
 1mg 
orb1890179-50mg
 50mg 
orb1299527-5mg
 5mg 
orb1890180-5mg
 5mg 
orb1227522-25mg
 25mg 
orb746819-100mg
 100mg 
orb1890182-10mg
 10mg 
orb1299527-200mg
 200mg 
orb1299527-50mg
 50mg